Log in

NASDAQ:AGIOAgios Pharmaceuticals Stock Price, Forecast & News

$50.40
-2.50 (-4.73 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$50.40
Now: $50.40
$53.50
50-Day Range
$47.14
MA: $51.60
$55.69
52-Week Range
$27.77
Now: $50.40
$56.74
Volume375,842 shs
Average Volume674,312 shs
Market Capitalization$3.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Read More
Agios Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.91 million
Book Value$10.88 per share

Profitability

Net Income$-411,470,000.00
Net Margins-205.20%

Miscellaneous

Employees482
Market Cap$3.47 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

How has Agios Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGIO shares have increased by 23.3% and is now trading at $50.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Agios Pharmaceuticals?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agios Pharmaceuticals.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Agios Pharmaceuticals.

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.67) by $1.08. The biopharmaceutical company had revenue of $87.10 million for the quarter, compared to analysts' expectations of $31.12 million. Agios Pharmaceuticals had a negative net margin of 205.20% and a negative return on equity of 63.85%. Agios Pharmaceuticals's revenue for the quarter was up 188.4% on a year-over-year basis. During the same quarter last year, the company earned ($1.59) earnings per share. View Agios Pharmaceuticals' earnings history.

What price target have analysts set for AGIO?

14 brokerages have issued 12-month target prices for Agios Pharmaceuticals' stock. Their forecasts range from $49.00 to $82.00. On average, they expect Agios Pharmaceuticals' share price to reach $69.67 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price. View analysts' price targets for Agios Pharmaceuticals.

Has Agios Pharmaceuticals been receiving favorable news coverage?

Media stories about AGIO stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a news impact score of -3.6 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Agios Pharmaceuticals.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Micron Technology (MU) and NVIDIA (NVDA).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the following people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Andrew J. Hirsch, CFO & Head-Corporate Development
  • Scott Biller, Chief Scientific Officer
  • Chris Bowden, Chief Medical Officer
  • Clive Patience, Senior Vice President-Technical Operations

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.01%) and Carroll Financial Associates Inc. (0.00%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, John Maraganore, Scott Biller and Steven L Hoerter. View institutional ownership trends for Agios Pharmaceuticals.

Which major investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including Carroll Financial Associates Inc.. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden. View insider buying and selling activity for Agios Pharmaceuticals.

Which major investors are buying Agios Pharmaceuticals stock?

AGIO stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse. View insider buying and selling activity for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $50.40.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $3.47 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is www.agios.com.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.